At EDDC, we believe that the best way to make progress in drug development is through innovation and collaboration. That is why we are constantly looking to build mutually beneficial partnerships with both public institutions and companies to develop novel treatments that can make a real difference to patients. Take a look at some of our successful collaborations and deals here.
US FDA approves Singapore’s first locally developed ADC for clinical trials
EBC-129 is the first made-in-Singapore Antibody-Drug Conjugate (ADC) that has been approved to enter clinical trials. This is an example of a successful multi-institutional collaboration in Singapore. Read the article to learn more about it!
Compounds against Tuberculosis out-licensed to Neuro-Horizon Pharma
This is a series of small molecule compounds co-developed by EDDC and Nanyang Technological University, Singapore (NTU Singapore) to combat multidrug-resistant Tuberculosis. They inhibit a key enzyme in the TB bacterium’s energy production pathway. Read the article to learn more about it!
Boehringer Ingelheim licenses series of innovative antibodies for targeted cancer therapies
Another example of a successful multi-institutional collaboration in Singapore. These innovative and highly-specific antibodies can be applied to a range of solid cancers, with the option of directing various different therapeutic modalities to the cancer cells. Read the article to learn more about it!
Potential COVID-19 oral antiviral treatments licensed by Everest Medicines
A special example of what our researchers are capable of - this series of in-house developed compounds have shown to inhibit a key enzyme of SARS-CoV-2 and its variants, as well as other coronaviruses such as MERS. Read the article to learn more about it!